Anavex Life Sciences Beat Consensus Estimates

Anavex Life Sciences (AVXL) reported a loss of $0.14 per share on revenue of $0.00 million for the fiscal first quarter ended December 2024. The consensus estimate was a loss of $0.17 per share. The company beat consensus estimates by 17.65%.

Anavex Life Sciences Corp. is a publicly traded biopharmaceutical company dedicated to the development of differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer’s disease, Parkinson’s disease, Rett syndrome and other central nervous system (CNS) diseases, pain, and various types of cancer.